Rhythm Pharmaceuticals (RYTM) Operating Expenses (2016 - 2026)

Rhythm Pharmaceuticals (RYTM) has 11 years of Operating Expenses data on file, last reported at $112.5 million in Q1 2026.

• On a quarterly basis, Operating Expenses rose 41.11% year-over-year to $112.5 million in Q1 2026; TTM through Mar 2026 was $414.5 million, a 33.94% increase from a year earlier, with the FY2025 full-year figure at $381.8 million, down 3.5% from the prior year.
• Operating Expenses for Q1 2026 stood at $112.5 million, up from $104.3 million in the prior quarter.
• Over the last five years, Operating Expenses for RYTM reached as high as $165.9 million in Q1 2024 and fell as low as $43.6 million in Q3 2022.
• Historically, Operating Expenses has averaged $79.7 million across 5 years, with a median of $69.6 million in 2024.
• Across the five-year window, Operating Expenses surged 159.15% in 2024 and plunged 51.94% in 2025, its largest moves.
• Year by year, Operating Expenses stood at $50.9 million in 2022, then rose by 28.7% to $65.5 million in 2023, then rose by 26.85% to $83.1 million in 2024, then climbed by 25.55% to $104.3 million in 2025, then climbed by 7.82% to $112.5 million in 2026.
• Per Business Quant data, the three most recent Operating Expenses figures were $112.5 million in Q1 2026, $104.3 million in Q4 2025, and $104.0 million in Q3 2025.